CDKN2A and acute lymphoblastic leukemia: To this end, aged mice were treated with Control Ig or T‐cell depleting antibodies followed by treatment with Control Ig or rIL‐37 prior to injection with BCR‐ABL1+/Arf‐null B‐ALL cells (Figure 5a).